Brandi Simpson is CEO for Navigen, Inc., a biopharmaceutical discovery and development company located in Salt Lake City.

Brandi started her career as an investment banking analyst at Merrill Lynch in New York City. While at Merrill, Brandi worked with clients on public stock offerings, acquisitions, acquisition defense strategies, and structured financings. Brandi then spent nearly 5 years working as a management consultant for Booz Allen & Hamilton.  At Booz, Brandi worked primarily in the life sciences practice on client projects ranging from new business development, strategic planning, acquisitions, and post-merger integration.  Ms. Simpson joined NPS Pharmaceuticals in 2002 where she served as Senior Director of Corporate Development and Strategy and then Senior Director of Investor Relations.  Brandi joined Navigen in 2007, serving as Chief Business Officer until her promotion to CEO in 2014.

Brandi received an Honors degree in Finance from the University of Utah. Brandi attended Stanford University's Graduate School of Business to earn an MBA.